Brought to you by 
Horizon Pharma buys Vidara Therapeutics for $660mm in cash and stock
19 Jun 2014
Executive Summary
Horizon Pharma Inc. (arthritis, pain, and inflammatory disease therapies) acquired privately held Ireland-based spec pharma Vidara Therapeutics Research Ltd. in a deal valued at $660mm ($200mm in cash and the rest paid out in Horizon stock). The combined entity will take the name Horizon Pharma PLC--with 74% of the entity’s shares owned by current Horizon shareholders, and the remaining 26% by Vidara--and will reside in Ireland.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Horizon Pharma buys Vidara Therapeutics for $660mm in cash and stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice